Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia

Percentage of Participants Achieving Objective Response Rate (ORR)

ORR is defined as CR + CRi + PR + nPR.

Time frame: Up to 12 Months

Time to First Response

Time to first response is defined as number of days from first venetoclax intake to first response.

Time frame: Up to approximately 36 Months

Time to Best Response

Time to best response is defined as number of days from first venetoclax intake to best response (CR, CRi, PR, nPR).

Time frame: Up to approximately 36 Months

Duration of Response (DoR)

Duration of Response (DoR) is defined as number of days from first response to disease progression or death from any cause, whichever comes first.

Time frame: Up to approximately 36 Months

Time to Next Treatment

Time to next treatment is defined as number of days from first venetoclax intake to first intake of next treatment including death from any cause.

Time frame: Up to approximately 36 Months

Minimal Residual Disease (MRD)

Percentage of participants achieving MRD (CLL \< 10000 leucocytes) in the bone marrow, peripheral blood, either and both will be assessed.

Time frame: Up to 36 Months

Overall Survival (OS)

OS is defined as the number of days from the date of first dose to the date of the observational period end or death for all dosed participants.

Time frame: Up to 36 Months

Progression-Free Survival (PFS)

PFS is defined as the interval (in days) between the first treatment day to the first sign of disease progression or death from any cause.

Time frame: Up to 36 Months

Number of Participants With Adverse Events (AEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

Time frame: Up to approximately 36 Months